Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,